Skip to main content
main-content
Erschienen in: Current Oncology Reports 2/2019

01.02.2019 | Leukemia (A Aguayo, Section Editor)

New Treatment Options for Acute Myeloid Leukemia in 2019

verfasst von: Marco Cerrano, Raphael Itzykson

Erschienen in: Current Oncology Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The extensive genomic characterization of acute myeloid leukemia (AML) led to the identification of a vast number of potential therapeutic targets. We review relevant data that have led to recent approval of new targeted therapies in AML and discuss the most promising drugs currently in development in this disease.

Recent Findings

New formulations of cytotoxic agents, namely CPX-351 and gemtuzumab ozogamicin, improve the outcome of defined subgroup of patients. Midostaurin added to intensive chemotherapy is approved in FLT3-mutated AML. More selective FLT3 inhibitors and the IDH inhibitors enasidenib and ivosidenib have shown significant single agent activity in the relapsed setting, and preliminary results of combination strategies are encouraging. The addition of the BCL2 inhibitor venetoclax appears to markedly improve the results of hypomethylating agents.

Summary

The therapeutic armamentarium of AML now includes novel cytotoxic drugs, drugs targeting recurrent oncogenes, or functional vulnerabilities of leukemic cells. Further work is required to optimize their integration to the current framework of AML management, including allogeneic stem cell transplantation.
Literatur
7.
Zurück zum Zitat Dombret H, Itzykson R. How and when to decide between epigenetic therapy and chemotherapy in patients with AML. Hematology Am Soc Hematol Educ Program. 2017;2017:45–53. PubMedPubMedCentral Dombret H, Itzykson R. How and when to decide between epigenetic therapy and chemotherapy in patients with AML. Hematology Am Soc Hematol Educ Program. 2017;2017:45–53. PubMedPubMedCentral
9.
Zurück zum Zitat Crisà E, Cerrano M, Gatti T, Giai V, Aguzzi C, Boccadoro M, et al. The combination of fludarabine + citarabine + idarubicin (FLAI), followed by post-remission maintenance, is a safe and effective treatment for elderly patients with AML or high risk MDS. Ann Hematol Oncol. 2015;2(8):1056. Crisà E, Cerrano M, Gatti T, Giai V, Aguzzi C, Boccadoro M, et al. The combination of fludarabine + citarabine + idarubicin (FLAI), followed by post-remission maintenance, is a safe and effective treatment for elderly patients with AML or high risk MDS. Ann Hematol Oncol. 2015;2(8):1056.
15.
Zurück zum Zitat Foran JM, Sun Z, Claxton DF, Lazarus HM, Thomas ML, Melnick A, et al. North American Leukemia, Intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age ≥60 years): a trial of the ECOG-ACRIN Cancer Research Group (E2906). ASH Meeting Abstracts 2015;126:217–217. Foran JM, Sun Z, Claxton DF, Lazarus HM, Thomas ML, Melnick A, et al. North American Leukemia, Intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age ≥60 years): a trial of the ECOG-ACRIN Cancer Research Group (E2906). ASH Meeting Abstracts 2015;126:217–217.
21.
Zurück zum Zitat • Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36:2684–92. https://​doi.​org/​10.​1200/​JCO.​2017.​77.​6112. This phase III trial showed the superiority of CPX-351 compared to 7+3 chemotherapy in elderly fit patients with secondary, therapy-related or de novo AML with myelodysplastic syndrome-related abnormalities. CrossRefPubMedPubMedCentral • Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36:2684–92. https://​doi.​org/​10.​1200/​JCO.​2017.​77.​6112. This phase III trial showed the superiority of CPX-351 compared to 7+3 chemotherapy in elderly fit patients with secondary, therapy-related or de novo AML with myelodysplastic syndrome-related abnormalities. CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat • Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial. Haematologica. 2018. https://​doi.​org/​10.​3324/​haematol.​2018.​188888. This is an independent review of the ALFA-0701 trial which confirmed the event-free survival advantage of addition of fractionated gemtuzumab ozogamicin to intensive chemotherapy. • Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial. Haematologica. 2018. https://​doi.​org/​10.​3324/​haematol.​2018.​188888. This is an independent review of the ALFA-0701 trial which confirmed the event-free survival advantage of addition of fractionated gemtuzumab ozogamicin to intensive chemotherapy.
35.
36.
Zurück zum Zitat Larson RA, Mandrekar SJ, Sanford BL, Laumann K, Geyer SM, Bloomfield CD, et al. An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. ASH Meeting Abstract 2017;130:145–145. Larson RA, Mandrekar SJ, Sanford BL, Laumann K, Geyer SM, Bloomfield CD, et al. An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. ASH Meeting Abstract 2017;130:145–145.
43.
Zurück zum Zitat Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia: sorafenib after HSCT for FLT3-mutated AML. Cancer. 2017;123:2867–74. https://​doi.​org/​10.​1002/​cncr.​30680. CrossRefPubMed Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia: sorafenib after HSCT for FLT3-mutated AML. Cancer. 2017;123:2867–74. https://​doi.​org/​10.​1002/​cncr.​30680. CrossRefPubMed
50.
Zurück zum Zitat Cortes JE, Kantarjian HM, Kadia TM, Borthakur G, Konopleva M, Garcia-Manero G, Daver NG, Pemmaraju N, Jabbour E, Estrov Z, Ramachandran A, Paradela J, Pond B, Ravandi F, Vusirikala M, Patel PA, Levis MJ, Perl AE, Andreeff M, Collins R Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. ASCO Meeting Abstracts 2016;34:7008–7008. https://​doi.​org/​10.​1200/​JCO.​2016.​34.​15_​suppl.​7008. Cortes JE, Kantarjian HM, Kadia TM, Borthakur G, Konopleva M, Garcia-Manero G, Daver NG, Pemmaraju N, Jabbour E, Estrov Z, Ramachandran A, Paradela J, Pond B, Ravandi F, Vusirikala M, Patel PA, Levis MJ, Perl AE, Andreeff M, Collins R Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. ASCO Meeting Abstracts 2016;34:7008–7008. https://​doi.​org/​10.​1200/​JCO.​2016.​34.​15_​suppl.​7008.
52.
Zurück zum Zitat • Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722–31. https://​doi.​org/​10.​1182/​blood-2017-04-779405. This large phase I/II trial evaluated enasidenib in IDH2-mutated relapsed/refractory AML, showing an overall response rate of 40%, and a prolonged duration of response in patients achieving complete remission. CrossRefPubMedPubMedCentral • Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722–31. https://​doi.​org/​10.​1182/​blood-2017-04-779405. This large phase I/II trial evaluated enasidenib in IDH2-mutated relapsed/refractory AML, showing an overall response rate of 40%, and a prolonged duration of response in patients achieving complete remission. CrossRefPubMedPubMedCentral
56.
Zurück zum Zitat • DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386–98. https://​doi.​org/​10.​1056/​NEJMoa1716984. Ivosidenib efficacy was demonstrated in this large phase I dose escalation and dose-expansion study including IDH1 -mutated relapsed/refractory AML patients. CrossRefPubMed • DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386–98. https://​doi.​org/​10.​1056/​NEJMoa1716984. Ivosidenib efficacy was demonstrated in this large phase I dose escalation and dose-expansion study including IDH1 -mutated relapsed/refractory AML patients. CrossRefPubMed
60.
Zurück zum Zitat Cortes JE, Heidel FH, Heuser M, Fiedler W, Smith BD, Robak T, et al. A phase 2 randomized study of low dose Ara-C with or without Glasdegib (PF-04449913) in untreated patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. ASH Meeting Abstracts 2016;128:99–99. Cortes JE, Heidel FH, Heuser M, Fiedler W, Smith BD, Robak T, et al. A phase 2 randomized study of low dose Ara-C with or without Glasdegib (PF-04449913) in untreated patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. ASH Meeting Abstracts 2016;128:99–99.
65.
Zurück zum Zitat Fröhling S, Agrawal M, Jahn N, Fransecky LR, Baldus CD, Wäsch R, et al. CDK4/6 inhibitor palbociclib for treatment of KMT2A-rearranged acute myeloid leukemia: interim analysis of the AMLSG 23-14 trial. ASH Meeting Abstracts. 2016;128:1608–1608. Fröhling S, Agrawal M, Jahn N, Fransecky LR, Baldus CD, Wäsch R, et al. CDK4/6 inhibitor palbociclib for treatment of KMT2A-rearranged acute myeloid leukemia: interim analysis of the AMLSG 23-14 trial. ASH Meeting Abstracts. 2016;128:1608–1608.
66.
Zurück zum Zitat Walker AR, Bhatnagar B, Marcondes AMQ, DiPaolo J, Vasu S, Mims AS, et al. Interim results of a phase 1b/2 study of entospletinib (GS-9973) monotherapy and in combination with chemotherapy in patients with acute myeloid leukemia. ASH Meeting Abstracts. 2016;128:2831–2831. Walker AR, Bhatnagar B, Marcondes AMQ, DiPaolo J, Vasu S, Mims AS, et al. Interim results of a phase 1b/2 study of entospletinib (GS-9973) monotherapy and in combination with chemotherapy in patients with acute myeloid leukemia. ASH Meeting Abstracts. 2016;128:2831–2831.
67.
Zurück zum Zitat Byrne M, Donnellan W, Patel MR, Zeidan AM, Cherry M, Baer MR, et al. Preliminary results from an ongoing phase 1/2 study of INCB053914, a pan-proviral integration sites for moloney virus (PIM) kinase inhibitor, in patients with advanced hematologic malignancies. ASH Meeting Abstracts. 2017;130:2585–2585. Byrne M, Donnellan W, Patel MR, Zeidan AM, Cherry M, Baer MR, et al. Preliminary results from an ongoing phase 1/2 study of INCB053914, a pan-proviral integration sites for moloney virus (PIM) kinase inhibitor, in patients with advanced hematologic malignancies. ASH Meeting Abstracts. 2017;130:2585–2585.
68.
Zurück zum Zitat Garcia-Manero G, Yang H, Fang Z, Kantarjian HM, DiNardo CD, Jabbour EJ, et al. Phase 1 results of FF-10501-01, a novel inosine 5’-monophosphate dehydrogenase inhibitor, in advanced acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), including hypomethylating agent (HMA) failures. ASH Meeting Abstracts. 2016;128:1640–1640. Garcia-Manero G, Yang H, Fang Z, Kantarjian HM, DiNardo CD, Jabbour EJ, et al. Phase 1 results of FF-10501-01, a novel inosine 5’-monophosphate dehydrogenase inhibitor, in advanced acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), including hypomethylating agent (HMA) failures. ASH Meeting Abstracts. 2016;128:1640–1640.
72.
Zurück zum Zitat Wei A, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL, et al. Phase 1/2 study of venetoclax with low-dose cytarabine in treatment-naive, elderly patients with acute myeloid leukemia unfit for intensive chemotherapy: 1-year outcomes. Blood. 2017;130:890. CrossRef Wei A, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL, et al. Phase 1/2 study of venetoclax with low-dose cytarabine in treatment-naive, elderly patients with acute myeloid leukemia unfit for intensive chemotherapy: 1-year outcomes. Blood. 2017;130:890. CrossRef
74.
Zurück zum Zitat • DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Blood. 2018. https://​doi.​org/​10.​1182/​blood-2018-08-868752. In this large phase Ib study in newly diagnosed elderly AML patients, venetoclax combined with hypomethylating agents led to a high remission rate and an overall survival higher than expected in this population. • DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Blood. 2018. https://​doi.​org/​10.​1182/​blood-2018-08-868752. In this large phase Ib study in newly diagnosed elderly AML patients, venetoclax combined with hypomethylating agents led to a high remission rate and an overall survival higher than expected in this population.
78.
81.
Zurück zum Zitat Khan M, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia TM, Huang X, et al. Randomized phase II trial of two schedules of decitabine as frontline therapy in elderly patients with acute myeloid leukemia ineligible for standard cytotoxic induction regimens. Blood. 2016;128:1612. CrossRef Khan M, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia TM, Huang X, et al. Randomized phase II trial of two schedules of decitabine as frontline therapy in elderly patients with acute myeloid leukemia ineligible for standard cytotoxic induction regimens. Blood. 2016;128:1612. CrossRef
82.
Zurück zum Zitat Huls G, Chitu D, Havelange V, Jongen-Lavrencic M, Loosdrecht A van de, Biemond BJ, et al. Randomized maintenance therapy with azacitidine (vidaza) in older patients (≥ 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t). results of the HOVON97 phase III randomized multicentre study (EudraCT 2008-001290-15). ASH Meeting Abstracts 2017;130:463–463. Huls G, Chitu D, Havelange V, Jongen-Lavrencic M, Loosdrecht A van de, Biemond BJ, et al. Randomized maintenance therapy with azacitidine (vidaza) in older patients (≥ 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t). results of the HOVON97 phase III randomized multicentre study (EudraCT 2008-001290-15). ASH Meeting Abstracts 2017;130:463–463.
84.
Zurück zum Zitat Cornelissen JJ, Norden Y van, Gelder M van, Breems DA, Maertens J, Jongen-Lavrencic M, et al. Early post-transplant epigenetic therapy by panobinostat and decitabine followed by donor lymphocyte infusion (DLI): interim results of the HOVON-116 phase I/II feasibility study in poor-risk AML recipients of allogeneic stem cell transplantation (alloHSCT). ASH Meeting Abstracts. 2016;128:832–832. Cornelissen JJ, Norden Y van, Gelder M van, Breems DA, Maertens J, Jongen-Lavrencic M, et al. Early post-transplant epigenetic therapy by panobinostat and decitabine followed by donor lymphocyte infusion (DLI): interim results of the HOVON-116 phase I/II feasibility study in poor-risk AML recipients of allogeneic stem cell transplantation (alloHSCT). ASH Meeting Abstracts. 2016;128:832–832.
90.
Zurück zum Zitat Manero GG, Atallah E, Khaled SK, Arellano M, Patnaik MM, Odenike O, et al. A phase 2 study of pracinostat and azacitidine in elderly patients with acute myeloid leukemia (AML) not eligible for induction chemotherapy: response and long-term survival benefit. ASH Meeting Abstracts. 2016;128:100–100. Manero GG, Atallah E, Khaled SK, Arellano M, Patnaik MM, Odenike O, et al. A phase 2 study of pracinostat and azacitidine in elderly patients with acute myeloid leukemia (AML) not eligible for induction chemotherapy: response and long-term survival benefit. ASH Meeting Abstracts. 2016;128:100–100.
Metadaten
Titel
New Treatment Options for Acute Myeloid Leukemia in 2019
verfasst von
Marco Cerrano
Raphael Itzykson
Publikationsdatum
01.02.2019
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 2/2019
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-019-0764-8

Weitere Artikel der Ausgabe 2/2019

Current Oncology Reports 2/2019 Zur Ausgabe

Palliative Medicine (A Jatoi, Section Editor)

Anticoagulation in Cancer Patients: a Summary of Pitfalls to Avoid

Evolving Therapies (RM Bukowski, Section Editor)

TRK Inhibitors: Clinical Development of Larotrectinib

Palliative Medicine (A Jatoi, Section Editor)

Novel Approaches for Treating Pain in Children

Neu im Fachgebiet Onkologie

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.